

# (12) International Application Status Report

**Received at International Bureau:** 30 May 2006 (30.05.2006)

**Information valid as of:** (..)

**Report generated on:** 18 January 2021 (18.01.2021)

**(10) Publication number:**

WO2006/094192

**(43) Publication date:**

08 September 2006 (08.09.2006)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/US2006/007598

**(22) Filing Date:**

03 March 2006 (03.03.2006)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

60/657,695 (US)

**(31) Priority date(s):**

03 March 2005 (03.03.2005)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

A61K 39/395 (2006.01); C12N 15/13 (2006.01)

**(71) Applicant(s):**

IMMUNOMEDICS, INC. [US/US]; 300 American Road Morris Plains, NJ 07950 (US) *(for all designated states except US)*

GOLDENBERG, David, M. [US/US]; 1 Charolais Farm Road Mendham, NJ 07945 (US) *(for US only)*

HANSEN, Hans, J. [US/US]; 6014 Angler Drive Picayune, MS 39466 (US) *(for US only)*

QU, Zhengxing [US/US]; 15 Sycamore Way Warren, NJ 07950 (US) *(for US only)*

CHANG, Chen-Hsing [US/US]; 349 French Circle Downingtown, PA 19335 (US) *(for US only)*

**(72) Inventor(s):**

GOLDENBERG, David, M.; 1 Charolais Farm Road Mendham, NJ 07945 (US)

HANSEN, Hans, J.; 6014 Angler Drive Picayune, MS 39466 (US)

QU, Zhengxing; 15 Sycamore Way Warren, NJ 07950 (US)

CHANG, Chen-Hsing; 349 French Circle Downingtown, PA 19335 (US)

**(74) Agent(s):**

HANSON, Roberta, J.; Faegre & Benson LLP Customer No. 35657 2200 Wells Fargo Center 90 South Seventh Street Minneapolis, MN 55402 (US)

**(54) Title (EN):** HUMANIZED L243 ANTIBODIES

**(54) Title (FR):** ANTICORPS HUMANISES L243

**(57) Abstract:**

**(EN):** Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.

**(FR):** L'invention a trait à des anticorps humanisés se liant spécifiquement aux HLA-DR. Les anticorps reconnaissent le site antigénique reconnu par l'anticorps monoclonal murin L243. L'invention concerne également des procédés de préparation de tels anticorps, ainsi que des compositions pharmaceutiques comprenant de tels anticorps, et des utilisations associées à la recherche, au diagnostic et au traitement clinique pour de tels anticorps.

**International search report:**

Received at International Bureau: 11 September 2006 (11.09.2006) [US]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

**(81) Designated States:**

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM